EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

The Effect of Thyrotropin Suppression on Survival Outcomes in Patients with Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis

Sriram Gubbi iD, Mohammad Al-Jundi, Peter Foerster, Stephanie Cardenas, Gisela Butera, Sungyoung Auh, Elizabeth Chalmers Wright, Joanna Klubo-Gwiezdzinska

Thyroid® · 2024-06 · 34 (6) · 674-686

DOI: 10.1089/thy.2023.0711 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Thyroid®, online erschienen am 24.06.2024. Verfasst von Sriram Gubbi und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyrotropin. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-term management of intermediate- and high-risk differentiated thyroid cancer (DTC) involves thyrotropin (TSH) suppression with thyroid hormone to prevent potential stimulation of TSH receptors on DTC cells, leading to tumor growth. However, the current guidelines recommending TSH suppression are based on low- to moderate-quality evidence.

Methods

We performed a systematic review and meta-analysis of studies evaluating the role of TSH suppression in intermediate- and high-risk DTC patients (≥18 years) treated as per regional guideline-based therapy with a follow-up duration of 5 years (PROSPERO #252396). TSH suppression was defined as “below normal reference range” or, when known,

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsThyrotropinHumansDisease-Free SurvivalProgression-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

TSH suppressionmeta-analysisprogression-free survivalsystematic reviewthyroid cancer

Substanzen

Thyrotropin

Autor:innen und Institutionen

  • National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Division of Library Services, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Sriram Gubbi

Förderung

  • Intramural NIH HHS

Zitieren

APA

Gubbi, S., Al-Jundi, M., Foerster, P., Cardenas, S., Butera, G., Auh, S., Wright, E. C., & Klubo-Gwiezdzinska, J. (2024). The Effect of Thyrotropin Suppression on Survival Outcomes in Patients with Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis. Thyroid®, 34(6), 674-686. https://doi.org/10.1089/thy.2023.0711

Vancouver

Gubbi S, Al-Jundi M, Foerster P, Cardenas S, Butera G, Auh S, et al. The Effect of Thyrotropin Suppression on Survival Outcomes in Patients with Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis. Thyroid®. 2024;34(6):674-686. doi:10.1089/thy.2023.0711

BibTeX
@article{Gubbi2024,
  author = {Gubbi, Sriram and Al-Jundi, Mohammad and Foerster, Peter and Cardenas, Stephanie and Butera, Gisela and Auh, Sungyoung and Wright, Elizabeth Chalmers and Klubo-Gwiezdzinska, Joanna},
  title = {The Effect of Thyrotropin Suppression on Survival Outcomes in Patients with Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis},
  journal = {Thyroid®},
  year = {2024},
  volume = {34},
  number = {6},
  pages = {674--686},
  doi = {10.1089/thy.2023.0711}
}
Kostenlos starten →